Australia's Adherium, a leader in respiratory eHealth, remote monitoring and data management solutions, has received US Food and Drug Administration (FDA) 510(k) clearance to market application connecting GlaxoSmithKline’s (GSK) Ellipta inhaler users with Adherium’s new, next generation Hailie sensor with physiological parameters for monitoring Asthma and Chronic obstructive pulmonary disease (COPD) medication use.

Following market clearance of the Hailie sensor with physiological parameters for AstraZeneca’s Symbicort pMDI inhaler, Adherium’s latest Hailie sensor is designed for use with the Breo, Anoro, Incruse, Trelegy and Arnuity Ellipta dry powder inhalers (DPIs), and captures physiological parameters, including inhalation duration, volume, and peak inhalation flow. This new series of devices provide a superior perspective into inhaler usage and technique giving patients and doctors immediate, real-time feedback thereby allowing patients to improve their quality of life and enabling physicians to enhance patient care by capturing clinical data supporting patient management and treatment.